International Journal of Clinical Pharmacy

, Volume 34, Issue 4, pp 538–546 | Cite as

Modelling drug-related morbidity in Sweden using an expert panel of pharmacists’

  • Hanna Gyllensten
  • Katja M. Hakkarainen
  • Anna K. Jönsson
  • Karolina Andersson Sundell
  • Staffan Hägg
  • Clas Rehnberg
  • Anders Carlsten
Research Article

Abstract

Background Drug-related morbidity (DRM) is common and to some extent preventable, and associated with considerable costs in patients attending hospital. In outpatients and in the general public corresponding data are limited, but pharmacists’ expert opinion has suggested high rates of DRM also in US ambulatory care. It is unknown if the results are applicable in Sweden today. Objective To estimate the proportions of patients with DRM and preventable DRM and the cost-of-illness (COI) of DRM in Sweden based on pharmacists’ expert opinion. Setting Swedish healthcare. Method The study applied a conceptual model of DRM based on a decision tree. An expert panel of pharmacists determined the probabilities of therapeutic outcomes of medication therapy. The COI analysis included direct costs from the healthcare perspective. Sensitivity analyses were performed for variations in probabilities and pathway costs. Main outcome measure DRM included new medical problems (adverse drug reactions, drug dependence and intoxications) and therapeutic failures (insufficient effects of medicines and morbidity due to untreated indication). Results The expert panel estimated that 61 ± 14 % (mean ± SD) of all patients attending healthcare suffered from DRM, of which 29 ± 8 % suffered from new medical problems, 18 ± 6 % from therapeutic failures, and 15 ± 7 % from a combination of both. The DRM was considered preventable in 45 ± 15 % of the patients with DRM. The estimated COI was EUR 997 per patient attending healthcare, corresponding to an annual cost of EUR 6,600 million to the Swedish healthcare system. The COI ranged from EUR 490 to EUR 1,314 when varying the participants’ probabilities of DRM and clinical outcomes from the first to the third quartile. Of the pathway costs, the COI was most sensitive to variation in the cost of prolonged hospital stay (COI range EUR 953–1,306). Conclusion According to pharmacists’ expert opinion, a large proportion of patients in Sweden experience DRM and preventable DRM, and the estimated COI of DRM is extensive. Since observational studies have not addressed the burden of DRM to the general public, this study adds the pharmacists’ perception on DRM. Other healthcare professionals’ perceptions on DRM need to be investigated in future studies.

Keywords

Adverse effects Cost of illness Decision trees Delphi technique Drug-related morbidity Drug therapy Preventability Sweden 

References

  1. 1.
    Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64(5):566–76.PubMedCrossRefGoogle Scholar
  2. 2.
    Jönsson AK, Spigset O, Tjäderborn M, Druid H, Hägg S. Fatal drug poisonings in a Swedish general population. BMC Clin Pharmacol. 2009;9:7.PubMedCrossRefGoogle Scholar
  3. 3.
    Leendertse AJ, Visser D, Egberts AC, van den Bemt PM. The relationship between study characteristics and the prevalence of medication-related hospitalizations: a literature review and novel analysis. Drug Saf. 2010;33(3):233–44.PubMedCrossRefGoogle Scholar
  4. 4.
    Kanjanarat P, Winterstein AG, Johns TE, Hatton PC, Segal R. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm. 2003;60(17):1750–9.PubMedGoogle Scholar
  5. 5.
    Thomsen LA, Winterstein AG, Søndergaard B, Haugbølle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother. 2007;41(9):1411–26.PubMedCrossRefGoogle Scholar
  6. 6.
    Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci. 2002;24(2):46–54.PubMedCrossRefGoogle Scholar
  7. 7.
    Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7):1017–25.PubMedCrossRefGoogle Scholar
  8. 8.
    Rodríguez-Monguió R, Otero MJ, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics. 2003;21(9):623–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995;155(18):1949–56.PubMedCrossRefGoogle Scholar
  10. 10.
    Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001;41(2):192–9.Google Scholar
  11. 11.
    Stark RG, John J, Leidl R. Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: a modelling approach. BMC Health Serv Res. 2011;11:9.PubMedCrossRefGoogle Scholar
  12. 12.
    Hallas J, Harvald B, Gram LF, Grodum E, Brosen K, Haghfelt T, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med. 1990;228(2):83–90.PubMedCrossRefGoogle Scholar
  13. 13.
    Nysam. Nyckeltal 2009 rapport Vårdkonsumtion. Swedish: The Association; 2010. p. 1–47.Google Scholar
  14. 14.
    Statistics Sweden. Sweden’s population nearing 9.5 million. [Updated 18 Feb 2011; cited 31 Jan 2012]. Available from: http://www.scb.se/Pages/PressRelease____308294.aspx.
  15. 15.
    Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997;277(4):307–11.PubMedCrossRefGoogle Scholar
  16. 16.
    Evans RS, Classen DC, Stevens LE, Pestotnik SL, Gardner RM, Lloyd JF, et al. Using a hospital information system to assess the effects of adverse drug events. Proc Annu Symp Comput Appl Med Care. 1993;161–5.Google Scholar
  17. 17.
    Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol. 1998;45(3):301–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring—cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf. 1997;6(Suppl 3):S79–90.PubMedCrossRefGoogle Scholar
  19. 19.
    Vargas E, Terleira A, Hernando F, Perez E, Cordon C, Moreno A, et al. Effect of adverse drug reactions on length of stay in surgical intensive care units. Crit Care Med. 2003;31(3):694–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Swedish Association of Local Authorities and Regions. Statistik om hälso-och sjukvård samt regional utveckling 2010. Swedish: The Association; 2011. p. 1–216.Google Scholar
  21. 21.
    Swedish Association of Local Authorities and Regions. Jämförelse av kostnader och verksamhet på sjukhuskliniker 2009. Swedish: The Association; 2010. p. 1–38.Google Scholar
  22. 22.
    Swedish Association of Local Authorities and Regions. Löne-och prisförändring för landsting och KPI. [Updated 27 May 2009; cited 31 Jan 2012]. Available from: http://www.skl.se/vi_arbetar_med/ekonomi/budget_och_planering/prisindex/landstingsprisindex.Swedish.
  23. 23.
    Sveriges Riksbank. Årsgenomsnitt valutakurser (ackumulerat). [Updated 1 Jan 2011; cited 31 Jan 2012]. Available from: http://www.riksbank.se/sv/Rantor-och-valutakurser/Arsgenomsnitt-valutakurser/. Swedish.
  24. 24.
    Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother. 2002;36(7–8):1238–48.PubMedCrossRefGoogle Scholar
  25. 25.
    Krähenbühl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krähenbühl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30(5):379–407.PubMedCrossRefGoogle Scholar
  26. 26.
    Henriksson F, Jönsson B. Diabetes: the cost of illness in Sweden. J Intern Med. 1998;244(6):461–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Statistics Sweden. Svenska hälsoräkenskaper 2001–2010. [Updated 30 Mar 2012; cited 20 Apr 2012]. Available from: http://www.scb.se/Pages/ProductTables____231546.aspx.Swedish.
  28. 28.
    Yousuf MI. Using experts’ opinions through Delphi techniques. Pract Assess Res Eval. 2007;12(4):1–8.Google Scholar
  29. 29.
    Brown BB. Delphi process: a methodology used for the elicitation of opinions of experts. RAND Corp. 1968;P-3925:1–14.Google Scholar
  30. 30.
    Karnon J, Brown J. Selecting a decision model for economic evaluation: a case study and review. Health Care Manag Sci. 1998;1(2):133–40.PubMedCrossRefGoogle Scholar
  31. 31.
    Rice DP. Estimating the cost of illness. Am J Public Health Nations Health. 1967;57(3):424–40.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Hanna Gyllensten
    • 1
  • Katja M. Hakkarainen
    • 1
  • Anna K. Jönsson
    • 2
    • 3
  • Karolina Andersson Sundell
    • 1
  • Staffan Hägg
    • 2
    • 3
  • Clas Rehnberg
    • 4
  • Anders Carlsten
    • 1
    • 5
  1. 1.Nordic School of Public Health NHVGöteborgSweden
  2. 2.Department of Drug Research/Clinical Pharmacology, Faculty of Health SciencesLinköping UniversityLinköpingSweden
  3. 3.Department of Clinical PharmacologyCounty Council of ÖstergötlandLinköpingSweden
  4. 4.Department of Learning, Informatics, Management and Ethics—LIMEKarolinska InstitutetStockholmSweden
  5. 5.Medical Products AgencyUppsalaSweden

Personalised recommendations